MetLife Investment Management LLC Purchases 1,190 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

MetLife Investment Management LLC raised its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 8.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 15,486 shares of the company's stock after buying an additional 1,190 shares during the period. MetLife Investment Management LLC's holdings in Medpace were worth $5,145,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of MEDP. Pallas Capital Advisors LLC boosted its holdings in Medpace by 179.7% during the 4th quarter. Pallas Capital Advisors LLC now owns 3,270 shares of the company's stock valued at $1,086,000 after acquiring an additional 2,101 shares during the period. Barclays PLC boosted its stake in shares of Medpace by 71.9% during the third quarter. Barclays PLC now owns 19,781 shares of the company's stock valued at $6,603,000 after purchasing an additional 8,275 shares during the period. Sanctuary Advisors LLC grew its holdings in shares of Medpace by 20.5% in the fourth quarter. Sanctuary Advisors LLC now owns 4,964 shares of the company's stock worth $1,738,000 after purchasing an additional 844 shares during the last quarter. SYM FINANCIAL Corp purchased a new stake in Medpace during the 4th quarter valued at $320,000. Finally, Tokio Marine Asset Management Co. Ltd. bought a new stake in Medpace in the 4th quarter worth $9,335,000. 77.98% of the stock is owned by institutional investors.

Insider Buying and Selling at Medpace

In other news, Director Fred B. Davenport, Jr. sold 1,712 shares of the firm's stock in a transaction dated Thursday, April 24th. The shares were sold at an average price of $301.82, for a total transaction of $516,715.84. Following the sale, the director now owns 2,998 shares of the company's stock, valued at $904,856.36. This trade represents a 36.35 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 20.30% of the company's stock.

Medpace Stock Up 1.4 %

Shares of NASDAQ:MEDP traded up $4.26 on Tuesday, hitting $302.44. 105,366 shares of the company traded hands, compared to its average volume of 339,238. The company has a market cap of $8.69 billion, a PE ratio of 23.80, a PEG ratio of 3.81 and a beta of 1.46. The stock has a 50 day simple moving average of $312.88 and a 200-day simple moving average of $331.26. Medpace Holdings, Inc. has a 52 week low of $250.05 and a 52 week high of $459.77.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its earnings results on Monday, April 21st. The company reported $3.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.06 by $0.61. Medpace had a net margin of 19.17% and a return on equity of 51.48%. The business had revenue of $558.57 million during the quarter, compared to analysts' expectations of $528.38 million. During the same period in the previous year, the company earned $3.20 earnings per share. As a group, sell-side analysts anticipate that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have commented on MEDP. TD Cowen lowered shares of Medpace from a "buy" rating to a "hold" rating and decreased their price objective for the stock from $370.00 to $328.00 in a report on Monday, April 14th. Leerink Partners began coverage on shares of Medpace in a research note on Monday, March 24th. They issued a "market perform" rating and a $330.00 price target for the company. Truist Financial cut their price objective on Medpace from $333.00 to $300.00 and set a "hold" rating on the stock in a research report on Wednesday, April 23rd. Robert W. Baird decreased their target price on Medpace from $340.00 to $313.00 and set a "neutral" rating for the company in a research report on Wednesday, April 23rd. Finally, Mizuho dropped their price target on Medpace from $400.00 to $355.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 9th. Eleven equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $349.30.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.